Clinical trialNCT05669833RecruitingPhase 3Interventional

Guselkumab vs Golimumab in PsA TNF Inadequate Responder Patients

SponsorUniversity of PennsylvaniaEnrollment63Psoriatic Arthritis

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The trial is an open-label randomized study that will examine whether switching to a selective IL23 inhibitor (guselkumab) is more effective than switching to a second TNFi (golimumab) among patients with PsA who have an inadequate response to a TNFi.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Alexis Ogdie-Beatty, MD, MSCE
University of Pennsylvania
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

14 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Family Arthritis Center
Loxahatchee Groves, Florida, United States
Howard Busch, DO
Recruiting
Healing Rheumatology
Plant City, Florida, United States
Gina Prakash, MD
Recruiting
Southwest Florida Rheumatology
Riverview, Florida, United States
Shanmugapriya Reddy, MD
Recruiting
Parris and Associates
Lilburn, Georgia, United States
Glenn Parris, MD
Recruiting
University of Massachusetts Chan Medical School
Worcester, Massachusetts, United States
Karen Salomon-Escoto, MD
Recruiting
University of Nebraska Medical Center
Omaha, Nebraska, United States
Ted Mikuls, MD
Recruiting
New York University
New York, New York, United States
Soumya Reddy, MD
Recruiting
Cincy Arthritis
Blue Ash, Ohio, United States
Tara Adhikari, MD
Recruiting
Southern Ohio Rheumatology
Wheelersburg, Ohio, United States
Rajesh Kataria, MD
Recruiting
Hospital at the University of Pennsylvania
Philadelphia, Pennsylvania, United States
Alexis Ogdie-Beatty, MD, MSCE
Recruiting
Cumberland Rheumatology
Crossville, Tennessee, United States
Sivalingam Kanagasegar, MD
Recruiting
Heritage Rheumatology and Arthritis Care
Colleyville, Texas, United States
Dhiman Basu, MD
Recruiting
Texas Arthritis Center
El Paso, Texas, United States
Sanjay Chabra, MD
Recruiting
University of Utah
Salt Lake City, Utah, United States
Jessica Walsh, MD
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Golimumab →Guselkumab →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 14 Jul 2023
Primary completion: 31 Oct 2026
Completion: 31 Oct 2026
Last update posted: 9 Oct 2025
Registered enrollment: 63
Registry id: NCT05669833

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.